Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Next Generation Sequencing Facilitates Quantitative Analysis of HHSteCs and HHSteC treated rhCYGB [HSC]

ABSTRACT: Purpose: Hepatic stellate cells (HSCs) plays an important role in liver fibrosis. Recombinant human Cytoglobin (rhCYGB) can inhibit the activation of HSCs. The goal of this study is to investigate the rhCYGB targeted signalling pathways regulating the activation of HSCs. Method: mRNA profiles of HHSteCs control and HHSteCs treated with rhCYGB (80 µg/ml, for 48 hour) were generated by deep sequencing. Results: The RNA-seq data confirmed that extracellular matrix-encoding genes and fibrosis-related genes were down-regulated by the His-CYGB treatment. The top of up-regulated genes following His-CYGB treatment were interferon (IFN)-stimulated genes (ISGs), implying IFN signaling in His-CYGB treatment.

ORGANISM(S): Homo sapiens

PROVIDER: GSE156779 | GEO | 2020/08/25

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Next Generation Sequencing Facilitates Quantitative Analysis of Control and rhCYGB treated liver transcriptomes [DDC]

Project description:Purpose: The goal of this study is to investigate the effect of recombinant human Cytoglobin (rhCYGB) on liver fibrosis induced by DDC diet in mice. Method: mRNA profiles of liver tissue of DDC-control mice and liver tissue of DDC-rhCYGB treated mice treated were generated by deep sequencing. Results: The RNA-seq data confirmed that extracellular matrix-encoding genes and fibrosis-related genes were down-regulated by the His-CYGB treatment.

2020-08-25 | GSE156778 | GEO

Next Generation Sequencing Facilitates Quantitative Analysis of Control and rhCYGB treated in MIA PaCa-2 cell line

Project description:Purpose: The goal of this study is to investigate the inhibitor effect of Cytoglobin on pancreatic cancer Method: mRNA profiles of control and rhCYGB treated pancreatic cancer cells were generated by deep sequencing. Results: The RNA-seq data confirmed that extracellular matrix-encoding genes and cell cycle regulated genes were down-regulated by the His-CYGB treatment.

2022-05-11 | GSE178358 | GEO

Next Generation Sequencing Facilitates Quantitative Analysis of Control and rhCYGB treated liver transcriptomes [TAA]

Project description:Purpose: The goal of this study is to investigate the effect of recombinant human Cytoglobin (rhCYGB) on liver fibrosis induced by TAA in mice. Method: mRNA profiles of liver tissues from TAA-control mice and TAA-rhCYGB treated mice were generated by deep sequencing. Results: The RNA-seq data confirmed that extracellular matrix-encoding genes and fibrosis-related genes were down-regulated by the rhCYGB treatment.

2020-08-25 | GSE156777 | GEO

Agilent HSC

Project description:Under conditions of the liver exposed to chronic insults such as viral infection, excess deposition of fat, regurgitation of bile acids etc., hepatic stellate cells (HSCs) change from quiescent to activated states and proliferate. During this process, HSCs secrete collagen and metalloproteinases. Involvement of collagen in sustaining activated HSC (aHSC) survival was postulated, although the precise mechanisms underlying the survival and apoptosis of aHSCs is still controversial. In this study, we compared the expression profiles between quiescent and activated HSCs to clarify the mechanisms of apoptosis for exploration of novel anti-fibrosis modalities.

2014-05-26 | E-MTAB-2081 | biostudies-arrayexpress

CYGB+ expressing vs non cytoglobin expressing cells (NCE) (MOCK)

Project description:CYGB+ expressing vs non cytoglobin expressing cells (NCE) (MOCK)

| PRJNA540265 | ENA

Cytoglobin dependent transcriptomic changes determine sensitivity of melanoma to ferroptopsis

Project description:In this study, we investigated the potential effect of CYGB on the cellular sensitivity towards (1S, 3R)-RAS-selective lethal small molecule (RSL3)-mediated ferroptosis in the G361 melanoma cells with abundant endogenous expression. Our findings show that an increased basal ROS level and higher degree of lipid peroxidation upon RSL3 treatment contributes to the increased sensitivity of CYGB knockdown G361 cells to ferroptosis. Furthermore, transcriptome analysis demonstrates the enrichment of multiple cancer malignancy pathways upon CYGB knockdown, supporting a tumor suppressive role for CYGB. Remarkably, CYGB knockdown also triggered activation of the NOD-, LRR- and pyrin domain-containing protein 3 (NLRP3) inflammasome and subsequent induction of pyroptosis target genes. Altogether, we show that silencing of CYGB expression modulates cancer therapy sensitivity via modulation of ferroptosis and pyroptosis cell death signalling pathways.

2022-07-29 | GSE209775 | GEO

HK1 from HSC-derived extracellular vesicles promotes HCC progression

Project description:Extracellular vesicles play crucial roles in intercellular communication in tumor microenvironment. Here, we demonstrate that in hepatic fibrosis, TGF-β stimulates the palmitoylation of hexokinase 1 (HK1) in hepatic stellate cells (HSCs), which facilitates the secretion of HK1 via large extracellular vesicles (lEVs) in a TSG101-dependent manner. The lEV HK1 is hijacked by hepatocellular carcinoma (HCC) cells, leading to accelerated glycolysis and HCC progression. In HSCs, the nuclear receptor Nur77 transcriptionally activates the expression of depalmitoylase ABHD17B to inhibit HK1 palmitoylation, consequently attenuating HK1 release. However, TGF-β-activated Akt functionally represses Nur77 by inducing Nur77 phosphorylation and degradation. We identify a small molecule PDNPA that binds Nur77 to generate steric hindrance to block Akt targeting, thereby disrupting Akt-mediated Nur77 degradation and preserving Nur77 inhibition of HK1 release. Together, this study demonstrates an overlooked function of HK1 in HCC upon its release from HSCs and highlights PDNPA as a candidate compound for inhibiting HCC progression.

2022-08-09 | PXD035911 | iProX

Gene Expression Patterns of Quiescent and Activated Mouse Primary Hepatic Stellate Cell (HSC)

Project description:Liver fibrosis is a manifestation of chronic liver injury. It leads to hepatic dysfunction and is a critical element in the pathogenesis of cirrhosis and hepatocellular carcinoma. The activation of hepatic stellate cells (HSC) plays a central role in liver fibrogenesis of different etiologies. To elucidate the molecular mechanism of this phenomenon, it is important to analyze the changes in gene expression that accompany the HSC activation process. In this study, we isolated quiescent and activated HSCs from control mice and mice with CCl4-induced liver fibrosis, respectively, and performed RNA sequencing to compare the differences in gene expression patterns between the two types of HSCs.

2020-04-29 | GSE149508 | GEO

Overexpression of CYGB led to differential gene expression in HCT116 cells (RNA-seq)

Project description:The goal of this study was to define the cohort of genes whose expression is regulated by CYGB function in colorectal cancer. Towards this goal, HCT116 cells stably expressing CYGB (HCT-CYGB) were established. In addition, a control cells (HCT-MOCK) was generated by transfection with empty vector. Subsequently, total RNA was isolated and then performed transcriptome RNA sequence.

2021-04-12 | GSE149426 | GEO

Next Generation Sequencing Facilitates Quantitative Analysis of HHSteCs, HHSteCs treated with Myoglobin (MB), HHSteCs treated with Neuroglobin (NGB)

Project description:Purpose: Hepatic stellate cells (HSCs) plays an important role in liver fibrosis. MB and NGB can inhibit the activation of HSCs. The goal of this study is to investigate the MB and NGB targeted signalling pathways regulating the activation of HSCs. Method: mRNA profiles of HHSteCs control, HHSteCs treated with MB (4 µM, for 48 hour), and HHSteCs treated with NGB (4 µM, for 48 hour) were generated by deep sequencing. Results: The RNA-seq data confirmed that extracellular matrix-encoding genes and fibrosis-related genes were down-regulated by the MB and NGB treatment.

2022-03-30 | GSE190258 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data